According to MercoPress, thyroid nodules are widespread, with estimates suggesting they occur in between half and seven in ten adults once people reach age 60. The outlet reported that this high baseline rate means many people who begin GLP-1 therapy will already have a nodule, whether it has been found or not, prior to their initial dose. MercoPress said that context matters when considering the black box warning attached to semaglutide and liraglutide, because having a nodule is not the same as having a risk caused by the drug, a distinction the outlet said is often blurred in informal conversations about the medicines.
Source: MercoPress.
